| Bid Price | 830.00p | High Price | 850.00p |
|---|
| Ask Price | 850.00p | Low Price | 850.00p |
|---|
| Open Price | 840.00p | Spread | 2.35% |
|---|
| Prev Close | 855.00p | Volume | 1,000 |
|---|
4Basebio PLC Historic Prices
| Date | Open | High | Low | Close | Volume |
|---|
| Sep 11, 2025 | 855.00 | 850.00 | 850.00 | 840.00 | 1,000 |
| Sep 10, 2025 | 855.00 | 880.00 | 830.50 | 855.00 | 3,935 |
| Sep 9, 2025 | 855.00 | 870.00 | 855.00 | 855.00 | 23 |
| Sep 8, 2025 | 885.00 | 904.60 | 850.00 | 855.00 | 2,814 |
4Basebio PLC Information
| Name | 4Basebio PLC | Index | FTSE AIM All Share |
|---|
| ISIN | GB00BMCLYF79 | Epic | 4BB |
|---|
| Type | Equity | Currency | GBX |
|---|
| Record Status | Active | Trading Segment | ASQ1 |
|---|
| Industry | Biotechnology | Sector | Healthcare |
|---|
| EMS | 200 | Trading Status | Closed |
|---|
| Shares in Issue | 15.48 m | Prev Close | 855.00p |
|---|
| PE Ratio | | Market Cap | £130.07 m |
|---|
| Div Yield | 0 | Div per Share | £NaN |
|---|
| EPS | -£0.49 | Div Cover | NaN |
|---|
| PEG | n/a | EPS Growth (%) | 0.00 |
|---|
| ROCE | -0.244147 | DPS Growth (%) | 0 |
|---|
| Current Ratio | 11.298009 | Quick Ratio | 10.685145 |
|---|
4Basebio PLC Director Deals
| Declared | Type | Director | Pos. | Volume / Price | Value |
|---|
| 04/04/25 | BUY | Heikki Lanckriet | CEO | 2,400 @ £12.05 | £28,920.00 |
| 03/03/25 | BUY | Amy Walker | ED | 1,151 @ £11.20 | £12,891.00 |
| 29/11/24 | BUY | Heikki Lanckriet | CEO | 12,000 @ £13.15 | £157,800.00 |
| 19/11/24 | BUY | Heikki Lanckriet | CEO | 93,000 @ £13.25 | £1,232,250.00 |
| 19/11/24 | SELL | Heikki Lanckriet | CEO | 93,000 @ £13.25 | £1,232,250.00 |
| 19/11/24 | BUY | Heikki Lanckriet | CEO | 46,500 @ £13.25 | £616,125.00 |
| 19/11/24 | SELL | Heikki Lanckriet | CEO | 46,500 @ £13.25 | £616,125.00 |
| 21/09/24 | SELL | Heikki Lanckriet | CEO | 315,706 @ £15.00 | £4,735,590.00 |
| 21/09/24 | SELL | David Roth | FD | 101,834 @ £15.00 | £1,527,510.00 |
| 21/09/24 | SELL | Joseph Fernandez | RES | 95,916 @ £15.00 | £1,438,740.00 |
4Basebio PLC News
